Thank you for your interest in new
Tralement™ (trace elements injection 4*, USP)
American Regent, Inc. is pleased to announce the pending availability of Tralement™ (trace elements injection 4*, USP),
the first and only FDA-approved multi-trace element injection.
Tralement™ was specifically developed to align with the American Society for Parenteral and Enteral Nutrition (ASPEN) recommendations for trace element supplementation1. See the table below for a listing of active ingredients contained in new Tralement™
Tralement™ is a combination of trace elements (zinc sulfate, cupric sulfate, manganese sulfate and selenious acid) indicated in adult and pediatric patients weighing at least 10 kg as a source of zinc, copper, manganese, and selenium for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated.
See the Important Safety Information for Tralement™ below, in addition to the product’s Full Prescribing Information
1. American Society for Parenteral and Enteral Nutrition (ASPEN) website:
http://www.nutritioncare.org/uploadedFiles/Documents/Guidelines_and_Clinical_Resources/PN%20Dosing%201-Sheet-FINAL.pdf. Accessed July 1, 2020.
Tralement™ is a trademark of American Regent, Inc.
Important Information on the Multiple Trace Element Product Line Transition
Helping you plan your inventory of Multiple Trace Element Products
During the first two weeks of November 2019, American Regent notified customers of our intent to stop manufacturing certain Multitrace® SKUs. We are currently supplying the following three products:
As required by the FDA, we will cease distribution of Multitrace®-5 Concentrate, 1 mL Single Dose Vial upon commercial availability of Tralement™ (trace elements injection 4, USP) 1 mL.
- The last order date for Multitrace®-5 Concentrate 1 mL will be August 20, 2020. We expect Tralement™ (trace elements injection 4, USP) 1 mL to be available and will begin accepting orders early September 2020.
After the availability of new FDA Approved Tralement™ we will offer the following multi-trace element products:
To receive updates on the availability of new Tralement™ (trace elements injection 4, USP), please complete the form below.
(8:30am–6pm Monday - Thursday and Friday 8:30am–5pm Eastern Time)
P: 888-354-4859E: firstname.lastname@example.org
(9am–5pm Eastern Time, Monday - Friday)
TRALEMENTTM (trace elements injection 4, USP)
For intravenous use
INDICATIONS AND USAGE
Tralement™ is indicated in adult and pediatric patients weighing at least 10 kg as a source of zinc, copper, manganese, and selenium for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated.
IMPORTANT SAFETY INFORMATION
Important Administration Information
Tralement is supplied as a single-dose vial for admixture use only. It is not for direct intravenous infusion. Prior to administration, Tralement must be transferred to a separate parenteral nutrition container, diluted and used as an admixture in parenteral nutrition solution.
Overview of Dosing
- Prior to administration of parenteral nutrition solution containing Tralement, correct severe fluid, electrolyte, and acid-base disorders.
- The dosage of the final parenteral nutrition solution containing Tralement must be based on the concentrations of all components in the solution, the patient’s clinical condition, nutritional requirements, and the contribution of oral or enteral intake.
Tralement is recommended only for patients who require supplementation with all four of the individual trace elements (i.e., zinc, copper, manganese and selenium).
See Full Prescribing Information on preparation, administration and dosing.
Tralement is contraindicated in patients with hypersensitivity to zinc or copper.
WARNINGS AND PRECAUTIONS
- Pulmonary Embolism due to Pulmonary Vascular Precipitates: If signs of pulmonary distress occur, stop the infusion and initiate a medical evaluation.
- Vein Damage and Thrombosis: Solutions with osmolarity of 900 mOsmol/L or more must be infused through a central catheter. The primary complication of peripheral access is venous thrombophlebitis.
- Neurologic Toxicity with Manganese: Monitor patients receiving long-term parenteral nutrition solutions containing Tralement for neurologic signs and symptoms and routinely monitor whole blood manganese concentrations and liver function tests. Discontinue Tralement and consider brain magnetic resonance imaging (MRI) if toxicity suspected.
- Hepatic Accumulation of Copper and Manganese: Assess for development of hepatic or biliary dysfunction. Monitor concentrations of copper and manganese in patients with cholestasis, biliary dysfunction or cirrhosis receiving Tralement long-term.
- Aluminum Toxicity: Tralement contains aluminum that may be toxic. Increased risk in patients with renal impairment, including preterm infants.
- Monitoring and Laboratory Tests: Monitor blood zinc, copper, manganese, and selenium concentrations, fluid and electrolyte status, serum osmolarity, blood glucose, liver and kidney function, blood count and coagulation parameters.
- Hypersensitivity Reactions with Zinc and Copper: If reactions occur, discontinue Tralement and initiate appropriate medical treatment.
The following adverse reactions were identified in clinical studies or post-marketing reports. Given that some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Adverse reactions with other components of parenteral nutrition solutions:
- Pulmonary embolism due to pulmonary vascular precipitates.
- Vein damage and thrombosis.
- Aluminum toxicity.
Adverse reactions with the use of trace elements administered parenterally or by other routes of administration:
- Neurologic toxicity with manganese
- Hepatic accumulation of copper and manganese
- Hypersensitivity reactions with zinc and copper
USE IN SPECIFIC POPULATIONS
Pregnancy - Risk Summary - Deficiency of trace elements may result in adverse pregnancy and fetal outcomes.
Lactation - Risk Summary - Zinc, copper, manganese, and selenium are present in human milk. The developmental and health benefits of breastfeeding should be considered, along with the mother’s clinical need for Tralement and any potential adverse effects on the breastfed infant from Tralement or from the underlying maternal condition.
Pediatric Use – Refer to Full Prescribing Information for dosing. Do not supplement Tralement with additional manganese. Tralement is not approved for use in pediatric patients weighing less than
Hepatic Impairment - Hepatic accumulation of copper and manganese have been reported with long-term administration in parenteral nutrition. For patients with cholestasis, biliary dysfunction, or cirrhosis, monitor hepatic and biliary function during long-term administration of Tralement.
OVERDOSAGE - There are reports on overdosage in the literature for the individual trace elements. Management of overdosage is supportive care based on presenting signs and symptoms.
For additional safety information, please see Full Prescribing Information.
You are encouraged to report Adverse Drug Events to American Regent Inc. at 1-800-734-9236, or to
the FDA by visiting www.fda.gov/medwatch or by calling 1-800-FDA-1088.